stockchase picture

Compiling comments that experts make about stocks while on public TV.

There are 0 registered members and 103 guests viewing this site

Company Index

List by Company Name

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

List by Symbol

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Abbott Labs

Stock Symbol: ABT-N

Last Price Recorded: 36.5900 on 2013-05-18 01:14:01

Globe 200 day average
Google Discussions (view only)
yahoo discussion
Date Signal Expert Opinion Price
2012-07-09 COMMENT Christine Poole Will be splitting the company into 2 parts, pharma side and medical devices. Purchased a generic company out of India last year and India will be providing health care to the general population but will only pay for generic drugs . Currently within a couple of dollars of her target price so she might shave some of her holdings.
Price:
$65.610
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2010-01-13 TOP PICK Gordon Reid Trading at about 13X earnings. Expects revenues to grow at 8%-10% and earnings to grow 12%-14%. 2.9% dividend. 7.5% free cash flow.
 Price:
$55.290
Subject:
US EQUITIES
Bias:
BULLISH on HEALTH CARE
Owned:
Yes
2012-04-19 BUY Stan Wong This is a more of a growth company in the healthcare space. You are looking at higher single-digit growth and you are getting it for around 11-12 times PE. Nice dividend at around 3.4%.
 Price:
$59.510
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
CAUTIOUS
Owned:
No
2012-05-17 TOP PICK David Burrows This has been one of the strong companies in the ethical drug companies. Have grown their dividend 10% at year over the last 10 years. Has been a very steady company. Traded sideways for 12 years in a price range and recently in the last year, broke out. They are going to split this company into a medical products/devices company and a pure pharma business. The pharma business will have a high yield attached and the other part has opportunities for efficiencies and growth.
 Price:
$62.230
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2010-05-27 DON'T BUY Brian Acker, CA The model price is $48.13, a 2% upside only. Fully priced.
 Price:
$47.870
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
No
2011-10-19 HOLD Stan Wong The market likes the split. Going to split into pharma and medical space. 3.6% dividend. Hold on to it for the time being.
Price:
$53.250
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
DEFENSIVE
Owned:
No
2012-03-15 TOP PICK Gavin Graham Splitting itself into two businesses – Pharma and Infant nutrition. Couple of interesting acquisitions in the last year and a half. 3.6% yield.
Price:
$59.110
Subject:
NORTH AMERICAN - LARGE & GLOBAL EQUITIES
Bias:
DEFENSIVE
Owned:
Yes
2003-09-03 BUY Brad Willock Spinning off their hospital products division. A good strategy as there is not much growth. Not too expensive.
 Price:
$41.750
Subject:
US LARGE
Bias:
CAUTIOUS
Owned:
Unknown
2011-10-20 BUY Barry Schwartz Restructuring came as a big surprise. Good valuation at 10X earnings. Long track record of raising dividends. Only real competition is Johnson & Johnson (JNJ-N) but feels this one has better growth. If they do the spinoff, they will probably stick with the non-pharma side of the business, which will be the better growth.
 Price:
$54.050
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2010-11-23 BUY Don Reed Recently checked back. Well managed and in good financial shape.
 Price:
$46.950
Subject:
GLOBAL EQUITIES
Bias:
OPTIMISTIC
Owned:
Yes
2011-05-24 BUY Barry Schwartz Raised dividend 30+ years in a row. Is going to show 10% earnings growth over next 2-3 years. A good space. They got too cheap so there is an opportunity.
Price:
$53.330
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Unknown
2001-12-10 BUY David Burrows Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
 Price:
$55.500
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUSLY OPTIMISTIC
Owned:
Unknown
2005-08-25 DON'T BUY David Burrows Pharmaceuticals is a group that has underperformed for about 3 years. This one, in relation to the rest of the group, has peformed better althoough all of them are retracing over the last couple of months. Prefers the bioceutical companies.
 Price:
$45.110
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
No
2010-04-26 TOP PICK Christine Poole Pharma company. Nutritional division. Adult’s nutrition. Likes the diversification. Consistently increases dividend, about 3-1/2% at present. Recently beat numbers. Pulled earning back by 7%, but it is manageable.
Price:
$50.370
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2011-04-27 BUY Gordon Reid Only a part of their business is in the pharma. Biggest drug is Humera for rheumatoid arthritis, which doesn’t go off patent until 2016. Also have a strong nutritional business. Earnings have grown every single year since 1991. Trades at about 11X earnings. Almost 4% dividend.
 Price:
$52.180
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
Showing 1 to 15 of 61 entries
First Previous 1 2 3 4 5 Next Last

No Comments.

You must be logged in to comment.